AbbVie Earnings Call: New Growth Engines Take Lead

Abbvie ((ABBV)) has held its Q4 earnings call. Read on for the main highlights of the call.

AbbVie Earnings Call Highlights Portfolio Strength Over Legacy Headwinds

AbbVie’s latest earnings call struck a decidedly upbeat tone, underscoring record revenues, earnings outperformance and powerful growth in its next-generation immunology and neuroscience franchises. Management acknowledged sizable setbacks from HUMIRA’s loss of exclusivity, weakness in parts of the aesthetics and oncology portfolios, and near‑term margin pressure from elevated R&D and deal-related costs. However, they repeatedly emphasized that the company’s diversified growth engines, robust pipeline, and expanding free cash flow leave AbbVie well positioned for sustained earnings and margin expansion into 2026 and beyond.

Record Revenue and EPS Outperformance

AbbVie reported full-year adjusted EPS of $10, beating the initial guidance midpoint by $0.54, while total net revenues (excluding acquired IPR&D) reached $61.2 billion, more than $2 billion above the company’s original outlook. Sales grew 8.6%, pushing revenues to an all‑time high that exceeded AbbVie’s prior peak by over $3 billion, even after absorbing nearly $16 billion in U.S. HUMIRA erosion since its loss of exclusivity. The company framed this as a key proof point that its transition away from reliance on HUMIRA is firmly on track, with newer products more than offsetting declines in the legacy blockbuster.

Immunology: SKYRIZI and RINVOQ Power the Growth Engine

Immunology remained the core driver of AbbVie’s performance, with fourth-quarter segment revenues of about $8.6 billion. SKYRIZI generated roughly $5 billion in Q4 sales, growing 31.9% on an operational basis, while RINVOQ delivered about $2.4 billion with 28.6% operational growth. For the full year, combined SKYRIZI and RINVOQ sales reached approximately $25.9 billion, up around $8 billion year over year. Management highlighted SKYRIZI’s continued penetration in inflammatory bowel disease (IBD), where global sales are expected to reach about $6.4 billion in 2025, more than double the prior year, and where it already captures over 45% U.S. biologic psoriasis share and roughly 75% of frontline “in-play” IBD patients. These two drugs are clearly positioned as the successor pillars to HUMIRA, with AbbVie signaling confidence they will continue to anchor long‑term growth despite modest pricing pressure.

Neuroscience Outperformance and Building a Parkinson’s Franchise

Neuroscience emerged as another standout, with full-year revenues surpassing $10.7 billion, an increase of roughly $1.8 billion versus the prior year, and fourth-quarter growth of 17.3% operationally. Vraylar contributed about $1 billion in Q4, Botox Therapeutic nearly $990 million, and oral migraine brands UBRELVY and QULYPTA added $339 million and $288 million, respectively. The company’s new Parkinson’s treatment, Violet, posted $183 million in Q4 revenue, up 33% sequentially, and management now expects it will reach blockbuster status in 2026. AbbVie is clearly leaning into neuroscience as a second growth platform, emphasizing the breadth of its portfolio and the runway for further penetration in depression, migraine and movement disorders.

Pipeline Progress and Elevated R&D Investment

AbbVie used the call to underscore its commitment to reinvesting in innovation, noting that adjusted R&D expense increased by nearly $1 billion in 2025 to fully fund about 90 clinical programs. Recent approvals included RINVOQ for giant cell arteritis (GCA), EMERALIS in nonsquamous non‑small cell lung cancer, and Epkinle in second-line follicular lymphoma. On the business development front, the company deployed more than $5 billion to secure platforms and assets in high-potential areas such as in‑vivo CAR T therapies, next‑generation psychedelics, trispecific antibodies, a long‑acting amylin analog (ABBV‑295), an siRNA platform, and a PD‑1/VEGF bispecific from Remagen. While these investments weigh on near‑term margins, management framed them as essential to building a durable pipeline that can support growth into the 2030s.

2026 Guidance and Margin Expansion Targets

Looking ahead to 2026, AbbVie guided for total net revenues of about $67 billion, implying 9.5% growth, and adjusted EPS in the range of $14.37 to $14.57, excluding any acquired IPR&D expense. The company expects an adjusted gross margin above 84% and a roughly 48.5% adjusted operating margin, signaling meaningful improvement versus 2025 as high-margin growth products scale and IPR&D charges normalize. Free cash flow is projected at roughly $18.5 billion, including about $3.5 billion of SKYRIZI royalties, providing ample capacity to sustain the dividend and pursue additional business development. Product-level guidance underscores AbbVie’s confidence in immunology ($34.5 billion, led by SKYRIZI at $21.5 billion and RINVOQ at $10.1 billion) and neuroscience ($12.5 billion) as the primary growth engines, even as oncology and aesthetics remain more mixed. Management also provided detailed first-quarter 2026 guidance, reinforcing the message of steady top- and bottom-line progression.

Strategic U.S. Agreement and Long‑Term Capital Commitments

AbbVie announced a voluntary three-year agreement with the U.S. government aimed at broadening patient access while supporting continued innovation. The arrangement includes a commitment to offer lower Medicaid prices and expanded direct-to-patient cash-pay options, coupled with a pledge to invest $100 billion in U.S. R&D and capital projects over the next decade. While financial details were not fully quantified, executives cast this as a strategic move to align the company with evolving policy expectations on drug affordability without derailing its long-term growth or innovation agenda. For investors, the deal signals AbbVie’s willingness to proactively shape the regulatory environment rather than respond reactively.

HUMIRA Erosion and Ongoing Access Pressure

HUMIRA’s decline remains a major drag, with U.S. erosion now totaling roughly $16 billion since loss of exclusivity. In the fourth quarter, global HUMIRA revenues were just over $1.2 billion, down 26.1% on an operational basis. Management warned that access pressure will intensify in 2026 as more payers shift to exclusive biosimilar contracts, and guided HUMIRA revenue to approximately $2.9 billion for that year. While the legacy blockbuster is shrinking faster than the overall company, AbbVie stressed that the impact is fully incorporated into its guidance and is being more than offset by growth from SKYRIZI, RINVOQ and the expanding neuroscience portfolio.

IMBRUVICA Decline and IRA‑Driven Oncology Headwinds

The oncology franchise faced a tougher backdrop, with IMBRUVICA’s fourth-quarter sales down 20.8% operationally and the broader oncology segment declining 2.5%. AbbVie expects continued pressure, with IMBRUVICA revenue guided to about $2.2 billion in 2026 and broader oncology growth constrained by pricing dynamics tied to U.S. policy changes such as the Inflation Reduction Act. While other oncology assets like VENCLEXTA and ELEHIR are expected to contribute growth, management conceded that the segment will be challenged to match the pace seen in immunology and neuroscience, and that pricing reform will remain an overhang for several years.

Aesthetics Weakness and Regional Share Losses

The aesthetics portfolio was another soft spot, with fourth-quarter sales of nearly $1.3 billion, down 1.2% operationally. Juvederm revenues fell 10.8% to $249 million, reflecting both competitive and macroeconomic pressures, while Botox Cosmetic grew a modest 3.8% to $717 million, lagging broader expectations for the category. AbbVie cited share losses in certain markets such as Brazil and macro headwinds impacting global discretionary spending. The company is working to stabilize share and reinvigorate growth through marketing and product initiatives, but investors were cautioned to expect a more gradual recovery in aesthetics than in AbbVie’s core therapeutic businesses.

Acquired IPR&D Costs Weigh on Margins and EPS

Acquired in‑process R&D (IPR&D) expenses significantly compressed reported profitability in the quarter, with a $0.71 unfavorable impact on EPS and a 7.6 percentage point drag on adjusted operating margin. These charges also pushed the adjusted tax rate up to 18.3% in Q4. Management argued that while these deal-related R&D costs create near‑term noise in earnings and margin metrics, they are the byproduct of deliberate investment in future growth platforms. Importantly, the company’s 2026 EPS guidance explicitly excludes acquired IPR&D, highlighting the underlying strength of the operating business once these episodic charges are stripped out.

Pricing and Policy Headwinds for Key Franchises

AbbVie flagged low single‑digit pricing headwinds for SKYRIZI and RINVOQ in 2026 and over the next several years, noting that RINVOQ faces a high single‑digit unfavorable comparison in the first quarter due to rebate timing in the prior year. In aesthetics, Botox has been selected for future Medicare price negotiations beginning later this decade, adding a layer of policy risk to one of AbbVie’s most recognizable brands. Management said they have planned conservatively for this scenario and do not expect it to materially alter long-term financial guidance, but acknowledged that policy and regulatory developments will remain a key variable for pricing and margins across the portfolio.

Forward‑Looking Guidance and Investor Takeaways

AbbVie’s forward guidance paints a picture of a company emerging from its HUMIRA patent cliff with renewed momentum. For 2026, the company is targeting about $67 billion in net revenues, underpinned by immunology sales of $34.5 billion and neuroscience revenues of $12.5 billion. Oncology is expected to contribute $6.5 billion and aesthetics $5.0 billion, with Botox Cosmetic and Juvederm remaining core contributors despite near-term softness. Adjusted EPS is projected between $14.37 and $14.57, supported by an adjusted gross margin above 84%, R&D spending around $9.7 billion, SG&A of roughly $14.2 billion, and an adjusted operating margin near 48.5%. Free cash flow is guided to approximately $18.5 billion, leaving room to fund dividends and additional deal-making. First-quarter 2026 guidance calls for revenues around $14.7 billion and adjusted EPS between $2.97 and $3.01, signaling a steady ramp toward the full-year targets.

In closing, AbbVie’s earnings call showcased a company successfully navigating one of the largest patent cliffs in pharma history while building new growth pillars in immunology and neuroscience. Record revenues and solid EPS upside, combined with robust guidance for 2026 and a deepening pipeline, helped offset concerns over HUMIRA’s ongoing erosion, oncology and aesthetics pressures, and near-term margin volatility from heavy R&D and policy headwinds. For investors, the message was clear: AbbVie’s transformation is well underway, and management believes the portfolio and balance sheet are strong enough to deliver sustained growth and expanding profitability in the years ahead.